Search Results for: ERBB3

Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
HINT1 histidine triad nucleotide binding protein 1
  • Regulation of MITF-M-dependent genes involved in apoptosis
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Adenosine phosphate
  • Guanosine-5'-Monophosphate
  • 5'-O-(N-Ethyl-Sulfamoyl)Adenosine
  • Adenosine-5'-ditungstate
  • 8-Bromo-Adenosine-5'-Monophosphate
HSH2D hematopoietic SH2 domain containing
HSPA1A heat shock protein family A (Hsp70) member 1A
  • Viral RNP Complexes in the Host Cell Nucleus
  • Regulation of HSF1-mediated heat shock response
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • Attenuation phase
  • HSF1-dependent transactivation
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Neutrophil degranulation
  • PKR-mediated signaling
  • Mitochondrial unfolded protein response (UPRmt)
  • Regulation of HSF1-mediated heat shock response
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • Attenuation phase
  • HSF1-dependent transactivation
  • Neutrophil degranulation
  • PKR-mediated signaling
  • Mitochondrial unfolded protein response (UPRmt)
HSPA8 heat shock protein family A (Hsp70) member 8
  • Regulation of HSF1-mediated heat shock response
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • Attenuation phase
  • HSF1-dependent transactivation
  • Lysosome Vesicle Biogenesis
  • Golgi Associated Vesicle Biogenesis
  • CHL1 interactions
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • mRNA Splicing - Major Pathway
  • Clathrin-mediated endocytosis
  • Protein methylation
  • GABA synthesis, release, reuptake and degradation
  • Lipophagy
  • Chaperone Mediated Autophagy
  • Late endosomal microautophagy
  • Respiratory syncytial virus genome transcription
  • PKR-mediated signaling
  • Dasatinib
  • (2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
  • Copper
  • Artenimol
IL6ST interleukin 6 cytokine family signal transducer
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Interleukin-35 Signalling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
ILKAP ILK associated serine/threonine phosphatase
INPPL1 inositol polyphosphate phosphatase like 1
  • Synthesis of PIPs at the plasma membrane
  • Synthesis of IP3 and IP4 in the cytosol
  • Interleukin receptor SHC signaling
  • Signaling by CSF1 (M-CSF) in myeloid cells
IRF2BP2 interferon regulatory factor 2 binding protein 2
ITK IL2 inducible T cell kinase
  • Generation of second messenger molecules
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Staurosporine
  • Pazopanib
  • Fostamatinib
  • Zanubrutinib
JAK2 Janus kinase 2
  • Interleukin-6 signaling
  • Interleukin-6 signaling
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • Prolactin receptor signaling
  • Prolactin receptor signaling
  • Signaling by SCF-KIT
  • Signaling by Leptin
  • RMTs methylate histone arginines
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF activation
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • IL-6-type cytokine receptor ligand interactions
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Cyclin D associated events in G1
  • Interferon gamma signaling
  • Regulation of IFNG signaling
  • Regulation of IFNG signaling
  • Interleukin-20 family signaling
  • Interleukin-35 Signalling
  • Signaling by Erythropoietin
  • Signaling by Erythropoietin
  • Interleukin-12 signaling
  • Interleukin-12 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-27 signaling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Potential therapeutics for SARS
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • IFNG signaling activates MAPKs
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Factors involved in megakaryocyte development and platelet production
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • XL019
  • 5-phenyl-1H-indazol-3-amine
  • 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
  • 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
  • Ruxolitinib
  • Tofacitinib
  • Pacritinib
  • Baricitinib
  • Entrectinib
  • Fostamatinib
  • Fedratinib
  • Abrocitinib
  • Zanubrutinib
  • Pralsetinib
  • Polycythemia vera
JAK3 Janus kinase 3
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by ALK
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • Interleukin-20 family signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-9 signaling
  • Interleukin-2 signaling
  • Interleukin-21 signaling
  • Interleukin receptor SHC signaling
  • Potential therapeutics for SARS
  • 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
  • R-348
  • Ruxolitinib
  • Tofacitinib
  • Baricitinib
  • Fostamatinib
  • Abrocitinib
  • Zanubrutinib
  • T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
JUP junction plakoglobin
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • Neutrophil degranulation
  • Keratinization
  • Formation of the cornified envelope
  • RHOA GTPase cycle
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RHOQ GTPase cycle
  • RHOH GTPase cycle
  • RHOJ GTPase cycle
  • Regulation of CDH11 function
  • Regulation of CDH11 function
  • Regulation of CDH19 Expression and Function
  • Regulation of CDH1 Function
  • Degradation of CDH1
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • CDH11 homotypic and heterotypic interactions
  • Zinc
  • Zinc acetate
  • Naxos disease and Carvajal syndrome
  • Arrhythmogenic right ventricular cardiomyopathy (ARVC)
LAMTOR2 late endosomal/lysosomal adaptor, MAPK and MTOR activator 2
  • Macroautophagy
  • MTOR signalling
  • mTORC1-mediated signalling
  • Energy dependent regulation of mTOR by LKB1-AMPK
  • TP53 Regulates Metabolic Genes
  • MAP2K and MAPK activation
  • Neutrophil degranulation
  • Regulation of PTEN gene transcription
  • Amino acids regulate mTORC1
LBHD1 LBH domain containing 1
LCK LCK proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Nef Mediated CD4 Down-regulation
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • Co-stimulation by CD28
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • Co-inhibition by CTLA4
  • Co-inhibition by PD-1
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RHOH GTPase cycle
  • Interleukin-2 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Dasatinib
  • AP-22408
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Zanubrutinib
  • Zotiraciclib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
LCP2 lymphocyte cytosolic protein 2
  • GPVI-mediated activation cascade
  • Generation of second messenger molecules
  • Generation of second messenger molecules
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
LRRC7 leucine rich repeat containing 7
LYN LYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated NF-kB activation
  • Co-stimulation by CD28
  • Co-inhibition by CTLA4
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • CD22 mediated BCR regulation
  • Cyclin D associated events in G1
  • Platelet Adhesion to exposed collagen
  • Signaling by Erythropoietin
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • Growth hormone receptor signaling
  • Growth hormone receptor signaling
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Bosutinib
  • Ponatinib
  • Nintedanib
  • Fostamatinib
MAP1B microtubule associated protein 1B
  • RSV-host interactions
MATK megakaryocyte-associated tyrosine kinase
  • Downregulation of ERBB2 signaling
  • Fostamatinib

Page 4 out of 11 pages